Pipeline
Product Development Portfolio
Inflammation
-
- Research
- Preclinical
- Phase 1
- Phase 2
- Phase 3
Obefazimod Phase 2b completed; First patient in phase 3 program enrolled in Oct. 2022Description/Summary:
Obefazimod is an oral, first-in-class, small molecule that has demonstrated safety and profound anti-inflammatory activity in preclinical trials and in Phase 2a and Phase 2b induction trials to treat ulcerative colitis (UC). Patients who completed the induction studies had the option to roll over into the respective open-label extension studies.
Milestones:
- Phase 2a data from 12-, 24- and 36-months maintenance study reported
- Phase 2b data from induction study reported
- Phase 2b data after 12-months reported from all 217 patients included into the maintenance study
-
- Research
- Preclinical
- Phase 1
- Phase 2
- Phase 3
Obefazimod Phase 2a completedDescription/Summary:
Obefazimod is an oral, first-in-class, small molecule that has demonstrated safety and profound anti-inflammatory activity in the completed Phase 2a and Phase 2b induction studies as well as in long-term maintenance studies in patients with moderate-to-severe ulcerative colitis (UC) and rheumatoid arthritis (RA). In addition to the clinical observations in UC patients, Abivax generated excellent phase 2a clinical results in the RA induction and subsequent maintenance study after one year of treatment.
Milestones:
- Phase 2a study results reported
- Phase 2a study results after one-year maintenance treatment reported
-
- Research
- Preclinical
- Phase 1
- Phase 2
- Phase 3
Obefazimod Phase 2b/3 pivotal study plannedDescription/Summary:
Obefazimod is an oral, first-in-class, small molecule that has demonstrated safety and profound anti-inflammatory activity in the completed Phase 2a and Phase 2b induction studies as well as in ongoing long-term maintenance studies in patients with moderate-to-severe ulcerative colitis (UC).
Due to the clinical similarities of Crohn’s disease (CD) and UC, and the predictability of the DSS model for both UC and CD, several key opinion leaders (KOLs) are confident that obefazimod will also show beneficial effects in patients suffering from CD.
Antiviral
-
Respiratory Syncytial Virus Antiviral drug
- Research
- Preclinical
- Phase 1
- Phase 2
- Phase 3
Cancer
-
- Research
- Preclinical
- Phase 1
- Phase 2
- Phase 3
ABX196 Phase 1/2 POC clinical trial in HCC – dose escalation phase completedDescription/Summary:
ABX196 has been developed as a synthetic agonist of iNKT cells from a proprietary platform technology that identifies cells with immune enhancing potential in cancer models.
Milestones:
- Results on dose escalation phase published at the ASCO GI Cancers Symposium 2022